VP & GM, Global Biologics
October 14, 2013
We look for ways of combining innovations around drug containment (such as the use of Daikyo Crystal Zenith®polymer syringes and customized drug containers) with expertise and understanding of patient needs to create solutions for tomorrow’s therapies and medications. And we’ve done so with a platform of system technologies.
The SmartDose® patch injector technology platform has been designed to meet the packaging and delivery needs of today’s biologic drugs. The Crystal Zenith polymer cartridge system enables effective and repeatable injection performance through dimensional precision. Electronic capabilities within the SmartDose system allow for programmable dosing, as well as enabling user feedback and monitoring.
The SelfDoseTM injector technology platform offers a simple, manually-activated injection system, compatible with ISO standard prefilled syringes. It enables the user to control the rate of injection, and provides needle hiding before and after injection. It has been designed with the needs of patients in mind, particularly those suffering from rheumatoid arthritis or those with limited dexterity.
The ConfiDose® auto-injector technology platform offer options for a standard 1mL long syringe or a customized 1.5mL Crystal Zenith polymer syringe. The system offers automatic injection of a single dose within a short period of time, and have been designed to be compatible with a range of syringes and viscosities.
For more information about any of these platforms, contact West today.
Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd.
Daikyo Crystal Zenith® technology is licensed from Daikyo Seiko, Ltd.
SelfDoseTM, SmartDose® and ConfiDose® are trademarks or registered trademarks of West Pharmaceutical Services, Inc., or its affiliated companies, in the United States and other jurisdictions.
West seeks partners for its injector technology platforms. These platforms are intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.